Rhizome AI
Product & Competitive Intelligence
Hallucination-free, citation-backed FDA regulatory intelligence for pharma and biotech.
Company Overview
Builds an AI-powered regulatory intelligence platform that uses retrieval-augmented generation and graph databases to deliver citation-backed, hallucination-free answers to complex FDA and global health authority questions for pharma, biotech, and medtech teams.
Competitive Advantage & Moat
Product Roadmap & Public Announcements
Rhizome AI reads up to 1,000 documents per question, accompanies each statement with a citation, and draws on 2.5TB of public data from FDA, EMA, MHRA, PMDA of Japan, and global clinical trial registries. Published pricing tiers (Project, Professional, Business, Enterprise) signal a land-and-expand GTM strategy. Exhibited at DIA RDISM 2026 conference. Expanding to additional regulatory authorities (Health Canada) and deeper postmarket/real-world evidence datasets.
Signals & Private Analysis
Chetan Mishra's prior experience at EvolutionaryScale (protein foundation models, sole founding product engineer) hints at potential future expansion into AI-driven biologics regulatory intelligence. Hiring Technical Implementation Manager suggests enterprise deployment scaling and push toward managed onboarding for large pharma clients. The LLM pulls guidance documents, approval packages, advisory committee materials, and clinical trial records directly from government portals. Pipelines clean, normalize, and rebuild materials into consistent structure from many formats including scanned PDFs.
Product Roadmap Priorities
AI-powered regulatory research assistant that delivers citation-backed, hallucination-free answers to complex FDA and global health authority questions in minutes instead of weeks.
It's like having a regulatory affairs expert who has memorized every FDA document ever published and can instantly show you the exact page where they found the answer.
It's like replacing a library research assistant who takes two weeks to find and photocopy the right pages with a photographic-memory savant who highlights the exact sentence you need before you finish asking the question.
Graph-based regulatory entity relationship mapping that connects drugs, devices, companies, enforcement actions, and approval pathways across global health authorities to surface hidden regulatory patterns and risks.
It's like connecting the dots between every FDA warning letter, device recall, and drug approval to spot trouble before it finds you.
It's like having a conspiracy theorist's wall of red string connecting photos and newspaper clippings—except it's actually accurate, covers every FDA document ever filed, and the connections are backed by real data instead of paranoia.
Automated regulatory document ingestion, classification, and normalization pipeline that continuously processes thousands of FDA and global health authority documents into a structured, searchable, and AI-ready knowledge base with weekly refresh cycles.
It's like having a tireless intern who reads every new FDA document the moment it's published, perfectly organizes it, and files it exactly where your AI can find it.
It's like a Roomba for regulatory paperwork—it quietly runs in the background, sucks up every new FDA document from every corner of the internet, sorts them into perfectly labeled folders, and never once complains about reading a 400-page guidance document at 3 AM.
Company Overview
Key Team Members
- Chetan Mishra, Founder & CEO
Founder Force Multiplier
Chetan Mishra joined EvolutionaryScale as their sole founding product engineer, launching an AI inference platform to help scientists design proteins and scaling to tens of thousands of users and billions of API calls. He was employee #16 at Instabase, helping banks with document and imaging processing and closing $7M as the technical lead. University of Virginia. He saw lots of AI drug discovery startups but very few focused on bringing drugs to market — navigating FDA expectations.
Funding History
- 2022 | Chetan Mishra founds Rhizome AI.
- 2025 | First funding round raised; platform development with 1,000+ documents across 30+ datasets.
- 2026 | Accepted into Y Combinator W26 batch; helping 18 organizations.
- 2026 | DIA RDISM 2026 conference booth; hiring Technical Implementation Manager.
Competitors
- Regulatory Intelligence Platforms: Veeva Vault RIM, Citeline (Pharma Intelligence), Cortellis (Clarivate).
- Regulatory Consulting: Regulatory Compliance Associates (RCA), PAREXEL.
- AI-Native Competitors: Lucem Health, various stealth regulatory AI startups.
- Traditional Search: Manual FDA.gov search, legal databases (Westlaw, LexisNexis for regulatory).
